Check 35,000+ stocks against 26 valuation models and 37 quality factors

Inhibikase Therapeutics Inc (IKT) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Inhibikase Therapeutics Inc $1.05, price $2.15, upside -51.4%, quality 21 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US · ISIN US45719W2052

Thin data Sep 24, 2026

Inhibikase Therapeutics Inc

IKT · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $1.05 · Strongly overvalued (−51%)

!Quality 21/100

!Weak Growth (revenue 5y −42.2 %/yr)

!negative free cash flow

!Trails peers (1/6)

!Narrow moat 3/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $0.6885 to bull $1.31 Growth analysisrevenue history, year by year Quality 21/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Inhibikase Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.8100 – $18.30 · fair‑value band $0.6885 – $1.31 · the $2.15 price screens above the $1.05 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Inhibikase Therapeutics in your weekly email

Every Wednesday you see whether Inhibikase Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Stock analysis

Inhibikase Therapeutics Inc (IKT) currently trades at $2.15, while our model-based Fair Value estimate is $1.05, implying the stock looks roughly 105.5% overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.6885 (bear) to $1.31 (bull), the price of $2.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Inhibikase Therapeutics Inc reported revenue of $0 in FY2025 versus $3.1M in FY2021. Reported net income was −$48.3M in FY2025.

Key figures

Market cap $375M · EPS (TTM) $−0.4200 · Return on equity −52.0% · Return on assets (EBIT) −60.7% · Revenue (TTM) $1 · Free cash flow −$27.8M · Net cash $139M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 15% below its 52-week high and 52% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −51%, IKT screens richer than that median.

Fair Value models

Bear $0.6885 Fair Value $1.05 Bull $1.31

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $0.6200 $0.8300 $1.24 51

All 1 models by family

Asset-Based

NCAV (Graham) $0.6200 $0.8300 $1.24 51

Open the full fair value analysis →

Notify me when IKT reaches fair value

Put IKT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 21/100

Of which business quality 29 · Market factors (momentum, volatility) 61

Profitability 0

Margins and returns on capital today

Quality Growth 56

Are margins and returns improving?

Cashflow 5

Earnings quality: real cash, not paper profit

Fin. Strength 100

Balance sheet, leverage, solvency risk

Investment 0

Disciplined investing over empire-building

Low Volatility 32

Calm price path (market factor)

Momentum 76

Price trend over the last 3–12 months (market factor)

52W Momentum 66

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+111.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−28.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−42.2%

Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−17.1%

’16

’17

’18

’19

’20

’21

’22

’23

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−52.5% (2018) → −7,712.0% (2023)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

IKT screens 106% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Inhibikase Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 1/5 measures

Overall it trails its industry peers.

Valuation

Quality Score 29 · Bottom 25%

Fair Value upside −51% · Below median

Profitability

Return on assets −33% · Bottom 25%

Operating margin (TTM) 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.17× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$514.99	$566.49	+10%
Regeneron Pharmaceuticals, Inc REGN	$803.90	$1,252	+56%
argenx SE ARGX	$963.79	$918.60	−5%
Samsung Biologics Co 207940	1,366,000 KRW	1,502,600 KRW	+10%
CSL Limited CSL	A$179.24	A$197.16	+10%
Alnylam Pharmaceuticals, Inc ALNY	$251.65	$218.36	−13%
Royalty Pharma plc RPRX	$58.52	$24.22	−59%
BeOne Medicines AG 6160	HK$218.20	HK$169.72	−22%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
BioNTech SE BNTX	$100.87	$63.62	−37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Inhibikase Therapeutics Inc · Fair Value
$1.05 −106%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/IKT" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Inhibikase Therapeutics Inc · Fair Value</span><br><b style="font-size:20px">$1.05</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−106%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Inhibikase Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/IKT

Frequently asked questions

Is Inhibikase Therapeutics Inc (IKT) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $1.05 versus a price of $2.15, about −51% upside (overvalued).

What is the fair value of IKT?

Our model-based fair value for Inhibikase Therapeutics Inc is $1.05 (as of Sep 24, 2026), built from audited fundamentals. The current price: $2.15.

What is the quality score of IKT?

Inhibikase Therapeutics Inc has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Inhibikase Therapeutics Inc (IKT)?

Our model-based price target is the fair value of $1.05 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.6885, optimistic scenario $1.31. It is a calculation from audited fundamentals, not an analyst target.

What is the Inhibikase Therapeutics Inc stock forecast for 2026?

Our models put fair value at $1.05, about −51% upside versus a price of $2.15 (overvalued). Cautious scenario $0.6885, optimistic scenario $1.31. The calculation is refreshed regularly with new filings.

What is the revenue of Inhibikase Therapeutics Inc (IKT)?

Inhibikase Therapeutics Inc reported trailing-twelve-month revenue of about $1 (latest available figure, as of Sep 24, 2026).

What is the intrinsic value of Inhibikase Therapeutics Inc (IKT)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inhibikase Therapeutics Inc it is $1.05 per share (as of Sep 24, 2026), against a price of $2.15. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Inhibikase Therapeutics Inc stock overvalued or undervalued in 2026?

As of Sep 24, 2026, IKT trades above its calculated fair value: price $2.15, fair value $1.05, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of IKT?

No. The price is what the market pays today ($2.15); the fair value is what the company's own numbers justify ($1.05). For Inhibikase Therapeutics Inc the two are $1.10 per share apart. That gap is exactly why we show both numbers side by side.

How much is Inhibikase Therapeutics Inc worth?

The market values Inhibikase Therapeutics Inc at about $375M (market capitalisation, as of Sep 24, 2026). Per share that is $2.15; our models calculate a fair value of $1.05 per share.

What do the bullish and bearish scenarios say about IKT?

Our models span a range for Inhibikase Therapeutics Inc: cautious scenario $0.6885, base $1.05, optimistic $1.31 per share (as of Sep 24, 2026, price $2.15). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Inhibikase Therapeutics Inc (IKT)?

Balance-sheet figures for Inhibikase Therapeutics Inc (as of Sep 24, 2026): return on equity −52.0%. They feed the Quality Score of 21/100, which measures business quality independently of the share price.

How far is IKT from its 52-week high?

Inhibikase Therapeutics Inc trades at $2.15, about 15% below its 52-week high of $2.52 and 52% above the low of $1.41 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $1.05 is for.

Which stocks are comparable to Inhibikase Therapeutics Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Inhibikase Therapeutics Inc stock attractive at the current price?

The data as of Sep 24, 2026: price $2.15, calculated fair value $1.05 (−51%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of IKT calculated?

We run Inhibikase Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.05, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Inhibikase Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Inhibikase Therapeutics Inc (IKT)?

The closing price on Sep 23, 2026 was $2.15. Our model-based fair value is $1.05, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Inhibikase Therapeutics Inc right now?

The price sits above even our optimistic bull case ($1.31). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.6885 to $1.31) leaves room in how you read the outcome.

Key figures of Inhibikase Therapeutics Inc

How large is the market capitalisation of Inhibikase Therapeutics Inc (IKT)?

The market capitalisation of Inhibikase Therapeutics Inc is $375M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Inhibikase Therapeutics Inc (IKT)?

Earnings per share at Inhibikase Therapeutics Inc are $−0.4200. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Inhibikase Therapeutics Inc (IKT)?

The return on equity (ROE) of Inhibikase Therapeutics Inc is −52.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Inhibikase Therapeutics Inc (IKT)?

On an EBIT basis the return on assets of Inhibikase Therapeutics Inc is −60.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How much free cash flow does Inhibikase Therapeutics Inc (IKT) generate?

The free cash flow of Inhibikase Therapeutics Inc is −$27.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Inhibikase Therapeutics Inc (IKT) hold?

Inhibikase Therapeutics Inc holds more cash than debt, $139M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Inhibikase Therapeutics Inc in the live analysis

One click puts Inhibikase Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.